IASO trial of anakinra for acute severe ulcerative colitis
Thursday, 02 March 2017 16:52
Despite huge progress in the outpatient management of ulcerative colitis, there are still around 2,500 admissions for acute severe UC in the UK every year. Our current standard initial therapy (intravenous corticosteroids) is based upon the landmark trial of Truelove and Witt in the 1950s; advances since have been restricted to rescue therapy for those failing this initial care. Led by Tim Raine and Arthur Kaser in Cambridge, with a team of researchers from across the UK, the IASO trial will be a multicentre, randomised, double-blind, placebo-controlled trial to test the hypothesis that IL-1 blockade using anakinra, a safe and affordable antagonist of the IL-1 receptor, can improve outcomes when given as initial therapy in acute severe UC alongside corticosteroids. Funding for IASO has been provided by the NIHR and MRC through the EME programme, with additional funding from the Wellcome Trust and Swedish Orphan Biovitrum, totalling in all in excess of £1.6m. IASO will set this major clinical trial in the context of a detailed scientific study of the largest cohort of patients with acute severe UC ever assembled. Patient recruitment will begin in 2017, with final trial reporting expected in 2021/22.
UEG's basic science offerings
Wednesday, 01 March 2017 11:59
UEG sent a recent newsletter outlining what they offer basic scientists.
Infographic on the drug discovery process
Tuesday, 28 February 2017 10:47
Compoundchem.com is an interesting website full of infographics relating to the role of chemistry in daily life. For example, last week, graphics were posted on chemistry in films and the composition of the Oscar statuettes. If this isn't your thing, you might be interested in an infographic on the drug discovery process with some accompanying text.
Top 20 pharma companies based on R&D investment 2015-16
Tuesday, 28 February 2017 10:01
IgeaHub published an infographic showing the top 20 pharma companies based on their R&D investment in 2015-16. The infographic was based on data extracted from the 2016 EU Industrial R&D Investment Scoreboard. The Scoreboard comprises the 2500 companies investing the largest sums in R&D in the world (€21m or more in each case) and an additional number of companies to cover the top 1000 R&D investing companies based in the EU (R&D of €6m or more). In total, there are 2909 parent companies incorporated in the 2016 Scoreboard. The EU Industrial R&D Investment Scoreboard is published annually by the European Commission (JRC-IPTS/DG RTD) as part of its Industrial Research and Innovation Monitoring and Analysis activity (IRIMA). In this 11.6 Mb report, the term EU company refers to companies whose ultimate parent has its registered office in a Member State of the EU. Likewise, non-EU company applies when the ultimate parent company is located outside the EU.
Page 5 of 39